-
Courier crosses the blood-brain barrier, and innovative therapy for ALS enters phase 2 clinical trials
Time of Update: 2022-05-27
▎WuXi AppTec Content Team Editor Recently, Denali Therapeutics announced that its partner, Sanofi, has started a Phase 2 clinical trial to test the efficacy and safety of SAR443820 (DNL788) in the treatment of amyotrophic lateral sclerosis (ALS) .
-
Science|Dr. Liu Dan et al. report the role of CD97 in maintaining homeostasis and function of type 2 dendritic cells in the spleen
Time of Update: 2022-03-07
Cyster at the University of California, San Francisco (first authors are Dan Liu and Dan Liu) published a research paper CD97 promotes spleen dendritic cell homeostasis through the mechanosensing of red blood cells in the journal Science, revealing that The role of CD97 in maintaining dendritic cell homeostasis in the spleen by mechanosensing red blood cells .
-
Alzheimers Dement︱Jinjing Yao et al found a new therapeutic target for Alzheimer's disease
Time of Update: 2022-01-25
Preliminary work in the laboratory of Professor Wayne Chen, University of Calgary, Canada, showed that shortening the open time of RyR2 can prevent and treat AD-related neuronal damage and cognitive decline in AD mouse models (5xFAD+/-).
-
Nature: Qinchuan et al. reveal the pathogenicity of SARS-CoV-2 in hACE2 genetically modified mice
Time of Update: 2020-05-13
2020 May 13 News / BioValley BIOON / - Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) led to the 2019 crown virus disease (COVID-19) case, has become a public health emergency of internatio